{
    "id": 1,
    "premise": "none",
    "hypothesis": "There are two potential treatment options for this patient.",
    "label": "entailment",
    "explanation": "Olaparib is a PARP1 inhibitor licenced for use in prostate cancer patients.\nRucaparib is a PARP1 inhibitor licenced for use in prostate cancer patients.\nPatients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA.",
    "results": {
        "semantic validity": false,
        "premise": null,
        "hypothesis": "There are two potential treatment options for this patient.",
        "history explanation": [
            "0 iteration: Olaparib is a PARP1 inhibitor licenced for use in prostate cancer patients.\nRucaparib is a PARP1 inhibitor licenced for use in prostate cancer patients.\nPatients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA.",
            "1 iteration: Olaparib is a PARP1 inhibitor licenced for use in prostate cancer patients.\nRucaparib is a PARP1 inhibitor licenced for use in prostate cancer patients.\nPatients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA.",
            "2 iteration: The interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients implies that the patient has two potential treatment options.",
            "3 iteration: The interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients implies that the patient has two potential treatment options.",
            "4 iteration: The interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients leads to the existence of two potential treatment options for the patient.\nThe patient having access to Olaparib and Rucaparib as PARP1 inhibitors implies that there are two potential treatment options available for the patient.",
            "5 iteration: The interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients leads to the existence of two potential treatment options for the patient.\nThe patient having access to Olaparib and Rucaparib as PARP1 inhibitors implies that there are two potential treatment options available for the patient.",
            "6 iteration: The interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients leads to the existence of two potential treatment options for the patient.\nThe patient having access to Olaparib and Rucaparib as PARP1 inhibitors implies that there are two potential treatment options available for the patient.",
            "7 iteration: The interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients leads to the existence of two potential treatment options for the patient.\nThe patient having access to Olaparib and Rucaparib as PARP1 inhibitors implies that there are two potential treatment options available for the patient.",
            "8 iteration: The interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients leads to the existence of two potential treatment options for the patient.\nThe patient having access to Olaparib and Rucaparib as PARP1 inhibitors implies that there are two potential treatment options available for the patient.",
            "9 iteration: The interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients leads to the existence of two potential treatment options for the patient.\nThe patient having access to Olaparib and Rucaparib as PARP1 inhibitors implies that there are two potential treatment options available for the patient.",
            "10 iteration: The interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients leads to the existence of two potential treatment options for the patient.\nThe patient having access to Olaparib and Rucaparib as PARP1 inhibitors implies that there are two potential treatment options available for the patient."
        ],
        "history semantic validity": [
            "0 iteration: False",
            "1 iteration: False",
            "2 iteration: False",
            "3 iteration: False",
            "4 iteration: False",
            "5 iteration: False",
            "6 iteration: False",
            "7 iteration: False",
            "8 iteration: False",
            "9 iteration: False",
            "10 iteration: False"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_1_0\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Olaparib :: \"entity \u21d2 bool\"\\n  Rucaparib :: \"entity \u21d2 bool\"\\n  PARP1Inhibitor :: \"entity \u21d2 bool\"\\n  LicencedForUseIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  ProstateCancerPatients :: \"entity \u21d2 entity\"\\n  Patient :: \"entity \u21d2 bool\"\\n  LossOfBRCA2 :: \"entity \u21d2 entity\"\\n  BenefitFrom :: \"entity \u21d2 entity \u21d2 bool\"\\n  PARP1Inhibition :: \"entity \u21d2 bool\"\\n  DueTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  SyntheticLethality :: \"entity \u21d2 bool\"\\n  Cause :: \"entity \u21d2 entity \u21d2 bool\"\\n  Cells :: \"entity \u21d2 entity\"\\n  RelyOn :: \"entity \u21d2 entity \u21d2 bool\"\\n  SingularMechanism :: \"entity \u21d2 entity\"\\n  Repair :: \"entity \u21d2 entity \u21d2 bool\"\\n  CumulativeDamageToDNA :: \"entity \u21d2 entity\"\\n\\n(* Explanation 1: Olaparib is a PARP1 inhibitor licenced for use in prostate cancer patients *)\\naxiomatization where\\n  explanation_1: \"\u2200x. Olaparib x \u27f6 (PARP1Inhibitor x \u2227 LicencedForUseIn x (ProstateCancerPatients x))\"\\n\\n(* Explanation 2: Rucaparib is a PARP1 inhibitor licenced for use in prostate cancer patients *)\\naxiomatization where\\n  explanation_2: \"\u2200x. Rucaparib x \u27f6 (PARP1Inhibitor x \u2227 LicencedForUseIn x (ProstateCancerPatients x))\"\\n\\n(* Explanation 3: Patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA *)\\naxiomatization where\\n  explanation_3: \"\u2200x y z. Patient x \u2227 LossOfBRCA2 y \u27f6 (BenefitFrom x y \u2227 DueTo y z \u2227 Cause z z \u2227 RelyOn z z \u2227 Repair z z)\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x\"\\n  (* Hypothesis: There are two potential treatment options for this patient *)\\n shows \"\u2203x y. Patient x \u2227 TreatmentOption y\"\\nproof -\\n  (* From the premise, we know that the patient x is a patient. *)\\n  from asm have \"Patient x\" <ATP>\\n  (* We have explanatory sentences 1 and 2 stating that Olaparib and Rucaparib are PARP1 inhibitors licensed for use in prostate cancer patients. *)\\n  (* There are logical relations Equivalent(A, B) and Equivalent(B, A). *)\\n  (* We can infer that Olaparib and Rucaparib are interchangeable in this context. *)\\n  (* Therefore, the patient x can benefit from both Olaparib and Rucaparib as treatment options. *)\\n  then have \"\u2203x y. Patient x \u2227 TreatmentOption y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Olaparib is a PARP1 inhibitor licenced for use in prostate cancer patients\\nB: Rucaparib is a PARP1 inhibitor licenced for use in prostate cancer patients\\nC: Patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA\\n\\nLogical Relations:\\nEquivalent(A, B)\\nEquivalent(Olaparib is a PARP1 inhibitor licenced for use in prostate cancer patients, Rucaparib is a PARP1 inhibitor licenced for use in prostate cancer patients)\\n--------\\n\\nDerived Implications:\\nImplies(Not(B), Not(A))\\nImplies(Not(Rucaparib is a PARP1 inhibitor licenced for use in prostate cancer patients), Not(Olaparib is a PARP1 inhibitor licenced for use in prostate cancer patients))\\n--------\\nImplies(Not(A), Not(B))\\nImplies(Not(Olaparib is a PARP1 inhibitor licenced for use in prostate cancer patients), Not(Rucaparib is a PARP1 inhibitor licenced for use in prostate cancer patients))\\n--------\\nImplies(B, A)\\nImplies(Rucaparib is a PARP1 inhibitor licenced for use in prostate cancer patients, Olaparib is a PARP1 inhibitor licenced for use in prostate cancer patients)\\n--------\\nImplies(A, B)\\nImplies(Olaparib is a PARP1 inhibitor licenced for use in prostate cancer patients, Rucaparib is a PARP1 inhibitor licenced for use in prostate cancer patients)\\n--------\\n'}",
            "1 iteration: {'syntactic validity': True, 'error code': '(* We have explanatory sentences 1 and 2 stating that Olaparib and Rucaparib are PARP1 inhibitors licenced for use in prostate cancer patients. *)\\n(* There are logical relations Equivalent(A, B) and Equivalent(B, A). *)\\n(* We can infer that Olaparib and Rucaparib are interchangeable in this context. *)\\n(* Therefore, the patient x has two potential treatment options. *)\\nthen have \"\u2203x y. Patient x \u2227 TreatmentOption y\" sledgehammer', 'solving time': 103.93588495254517, 'proof tactics': [], 'code': 'theory clinical_1_1\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Olaparib :: \"entity \u21d2 bool\"\\n  Rucaparib :: \"entity \u21d2 bool\"\\n  PARP1Inhibitor :: \"entity \u21d2 bool\"\\n  LicencedForUseIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  ProstateCancerPatients :: \"entity \u21d2 entity\"\\n  Patient :: \"entity \u21d2 bool\"\\n  LossOfBRCA2 :: \"entity \u21d2 bool\"\\n  PARP1Inhibition :: \"entity \u21d2 bool\"\\n  SyntheticLethality :: \"entity \u21d2 bool\"\\n  Cause :: \"entity \u21d2 bool\"\\n  CellsRelianceOn :: \"entity \u21d2 entity \u21d2 bool\"\\n  CumulativeDamageToDNA :: \"entity \u21d2 bool\"\\n  BenefitFrom :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Olaparib is a PARP1 inhibitor licenced for use in prostate cancer patients *)\\naxiomatization where\\n  explanation_1: \"\u2200x. Olaparib x \u27f6 (PARP1Inhibitor x \u2227 LicencedForUseIn x (ProstateCancerPatients x))\"\\n\\n(* Explanation 2: Rucaparib is a PARP1 inhibitor licenced for use in prostate cancer patients *)\\naxiomatization where\\n  explanation_2: \"\u2200x. Rucaparib x \u27f6 (PARP1Inhibitor x \u2227 LicencedForUseIn x (ProstateCancerPatients x))\"\\n\\n(* Explanation 3: Patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA *)\\naxiomatization where\\n  explanation_3: \"\u2200x y. Patient x \u2227 LossOfBRCA2 x \u2227 PARP1Inhibition y \u2227 SyntheticLethality y \u2227 Cause y \u2227 CellsRelianceOn x (RepairMechanism y) \u2227 CumulativeDamageToDNA x \u27f6 BenefitFrom x y\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x\"\\n  (* Hypothesis: There are two potential treatment options for this patient *)\\n shows \"\u2203x y. Patient x \u2227 TreatmentOption y\"\\nproof -\\n  (* From the premise, we know that the patient x exists. *)\\n  from asm have \"Patient x\" <ATP>\\n  (* We have explanatory sentences 1 and 2 stating that Olaparib and Rucaparib are PARP1 inhibitors licenced for use in prostate cancer patients. *)\\n  (* There are logical relations Equivalent(A, B) and Equivalent(B, A). *)\\n  (* We can infer that Olaparib and Rucaparib are interchangeable in this context. *)\\n  (* Therefore, the patient x has two potential treatment options. *)\\n  then have \"\u2203x y. Patient x \u2227 TreatmentOption y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Olaparib is a PARP1 inhibitor licenced for use in prostate cancer patients\\nB: Rucaparib is a PARP1 inhibitor licenced for use in prostate cancer patients\\nC: Patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA\\n\\nLogical Relations:\\nEquivalent(A, B)\\nEquivalent(Olaparib is a PARP1 inhibitor licenced for use in prostate cancer patients, Rucaparib is a PARP1 inhibitor licenced for use in prostate cancer patients)\\n--------\\n\\nDerived Implications:\\nImplies(Not(B), Not(A))\\nImplies(Not(Rucaparib is a PARP1 inhibitor licenced for use in prostate cancer patients), Not(Olaparib is a PARP1 inhibitor licenced for use in prostate cancer patients))\\n--------\\nImplies(Not(A), Not(B))\\nImplies(Not(Olaparib is a PARP1 inhibitor licenced for use in prostate cancer patients), Not(Rucaparib is a PARP1 inhibitor licenced for use in prostate cancer patients))\\n--------\\nImplies(B, A)\\nImplies(Rucaparib is a PARP1 inhibitor licenced for use in prostate cancer patients, Olaparib is a PARP1 inhibitor licenced for use in prostate cancer patients)\\n--------\\nImplies(A, B)\\nImplies(Olaparib is a PARP1 inhibitor licenced for use in prostate cancer patients, Rucaparib is a PARP1 inhibitor licenced for use in prostate cancer patients)\\n--------\\n'}",
            "2 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 10.309743642807007, 'proof tactics': ['Type unification failed: Clash of types \"entity\" and \"event\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  Patient :: event \\\\<Rightarrow> entity \\\\<Rightarrow> bool\\nOperand:   z :: entity\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_1_2\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Olaparib :: \"entity \u21d2 bool\"\\n  Rucaparib :: \"entity \u21d2 bool\"\\n  PARP1Inhibitor :: \"entity \u21d2 bool\"\\n  ProstateCancerPatient :: \"entity \u21d2 bool\"\\n  LicensedFor :: \"entity \u21d2 entity \u21d2 bool\"\\n  Implies :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  TreatmentOption :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: The interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients implies that the patient has two potential treatment options *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w e1 e2. Olaparib x \u2227 Rucaparib y \u2227 PARP1Inhibitor z \u2227 ProstateCancerPatient w \u2227 LicensedFor w z \u2227 Implies e1 \u2227 Patient e2 w \u2227 TreatmentOption x \u2227 TreatmentOption y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"ProstateCancerPatient z\"\\n  (* Hypothesis: There are two potential treatment options for this patient *)\\n  shows \"\u2203x y. TreatmentOption x \u2227 TreatmentOption y \u2227 Patient z x \u2227 Implies x \u2227 Implies y\"\\nproof -\\n  (* From the premise, we know that the patient is a Prostate Cancer Patient. *)\\n  from asm have \"ProstateCancerPatient z\" <ATP>\\n  (* There is a logical relation Implies(C, D), Implies(interchangeability of Olaparib and Rucaparib as PARP1 inhibitors, the patient has two potential treatment options) *)\\n  (* We can derive Implies(A, C) and Implies(B, C) from the logical relations. *)\\n  (* From Implies(A, C), we can infer that Olaparib is a PARP1 inhibitor licensed for use in prostate cancer patients. *)\\n  then have \"Olaparib x\" for x <ATP>\\n  (* From Implies(B, C), we can infer that Rucaparib is a PARP1 inhibitor licensed for use in prostate cancer patients. *)\\n  then have \"Rucaparib y\" for y <ATP>\\n  (* There is a logical relation Implies(A, D), Implies(Olaparib is a PARP1 inhibitor licensed for use in prostate cancer patients, the patient has two potential treatment options) *)\\n  (* From Implies(A, D), we can conclude that there is a treatment option related to Olaparib. *)\\n  then obtain x where \"TreatmentOption x \u2227 Patient z x \u2227 Implies x\" <ATP>\\n  (* There is a logical relation Implies(B, D), Implies(Rucaparib is a PARP1 inhibitor licensed for use in prostate cancer patients, the patient has two potential treatment options) *)\\n  (* From Implies(B, D), we can conclude that there is a treatment option related to Rucaparib. *)\\n  then obtain y where \"TreatmentOption y \u2227 Patient z y \u2227 Implies y\" <ATP>\\n  (* Combining the treatment options related to Olaparib and Rucaparib, we have proved the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Olaparib is a PARP1 inhibitor licensed for use in prostate cancer patients\\nB: Rucaparib is a PARP1 inhibitor licensed for use in prostate cancer patients\\nC: interchangeability of Olaparib and Rucaparib as PARP1 inhibitors\\nD: the patient has two potential treatment options\\n\\nLogical Relations:\\nEquivalent(A, C)\\nEquivalent(Olaparib is a PARP1 inhibitor licensed for use in prostate cancer patients, interchangeability of Olaparib and Rucaparib as PARP1 inhibitors)\\n--------\\nEquivalent(B, C)\\nEquivalent(Rucaparib is a PARP1 inhibitor licensed for use in prostate cancer patients, interchangeability of Olaparib and Rucaparib as PARP1 inhibitors)\\n--------\\nImplies(C, D)\\nImplies(interchangeability of Olaparib and Rucaparib as PARP1 inhibitors, the patient has two potential treatment options)\\n--------\\n\\nDerived Implications:\\nImplies(Not(D), Not(B))\\nImplies(Not(the patient has two potential treatment options), Not(Rucaparib is a PARP1 inhibitor licensed for use in prostate cancer patients))\\n--------\\nImplies(C, B)\\nImplies(interchangeability of Olaparib and Rucaparib as PARP1 inhibitors, Rucaparib is a PARP1 inhibitor licensed for use in prostate cancer patients)\\n--------\\nImplies(A, C)\\nImplies(Olaparib is a PARP1 inhibitor licensed for use in prostate cancer patients, interchangeability of Olaparib and Rucaparib as PARP1 inhibitors)\\n--------\\nImplies(Not(B), Not(A))\\nImplies(Not(Rucaparib is a PARP1 inhibitor licensed for use in prostate cancer patients), Not(Olaparib is a PARP1 inhibitor licensed for use in prostate cancer patients))\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(interchangeability of Olaparib and Rucaparib as PARP1 inhibitors), Not(Olaparib is a PARP1 inhibitor licensed for use in prostate cancer patients))\\n--------\\nImplies(Not(B), Not(C))\\nImplies(Not(Rucaparib is a PARP1 inhibitor licensed for use in prostate cancer patients), Not(interchangeability of Olaparib and Rucaparib as PARP1 inhibitors))\\n--------\\nImplies(B, D)\\nImplies(Rucaparib is a PARP1 inhibitor licensed for use in prostate cancer patients, the patient has two potential treatment options)\\n--------\\nImplies(C, A)\\nImplies(interchangeability of Olaparib and Rucaparib as PARP1 inhibitors, Olaparib is a PARP1 inhibitor licensed for use in prostate cancer patients)\\n--------\\nImplies(A, D)\\nImplies(Olaparib is a PARP1 inhibitor licensed for use in prostate cancer patients, the patient has two potential treatment options)\\n--------\\nImplies(Not(C), Not(B))\\nImplies(Not(interchangeability of Olaparib and Rucaparib as PARP1 inhibitors), Not(Rucaparib is a PARP1 inhibitor licensed for use in prostate cancer patients))\\n--------\\nImplies(Not(A), Not(C))\\nImplies(Not(Olaparib is a PARP1 inhibitor licensed for use in prostate cancer patients), Not(interchangeability of Olaparib and Rucaparib as PARP1 inhibitors))\\n--------\\nImplies(Not(D), Not(A))\\nImplies(Not(the patient has two potential treatment options), Not(Olaparib is a PARP1 inhibitor licensed for use in prostate cancer patients))\\n--------\\nImplies(Not(A), Not(B))\\nImplies(Not(Olaparib is a PARP1 inhibitor licensed for use in prostate cancer patients), Not(Rucaparib is a PARP1 inhibitor licensed for use in prostate cancer patients))\\n--------\\nImplies(B, A)\\nImplies(Rucaparib is a PARP1 inhibitor licensed for use in prostate cancer patients, Olaparib is a PARP1 inhibitor licensed for use in prostate cancer patients)\\n--------\\nImplies(A, B)\\nImplies(Olaparib is a PARP1 inhibitor licensed for use in prostate cancer patients, Rucaparib is a PARP1 inhibitor licensed for use in prostate cancer patients)\\n--------\\nImplies(B, C)\\nImplies(Rucaparib is a PARP1 inhibitor licensed for use in prostate cancer patients, interchangeability of Olaparib and Rucaparib as PARP1 inhibitors)\\n--------\\n'}",
            "3 iteration: {'syntactic validity': True, 'error code': 'then show ?thesis sledgehammer', 'solving time': 119.6526894569397, 'proof tactics': [], 'code': 'theory clinical_1_3\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Olaparib :: \"entity \u21d2 bool\"\\n  Rucaparib :: \"entity \u21d2 bool\"\\n  PARP1Inhibitor :: \"entity \u21d2 bool\"\\n  ProstateCancerPatient :: \"entity \u21d2 bool\"\\n  Implies :: \"event \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  TreatmentOption :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: The interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients implies that the patient has two potential treatment options. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w e1. Olaparib x \u2227 Rucaparib y \u2227 PARP1Inhibitor z \u2227 ProstateCancerPatient w \u2227 Implies e1 \u2227 Patient w \u2227 TreatmentOption x \u2227 TreatmentOption y\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient z\"\\n  (* Hypothesis: There are two potential treatment options for this patient. *)\\n shows \"\u2203x y. TreatmentOption x \u2227 TreatmentOption y \u2227 Patient z \u2227 For z y\"\\nproof -\\n  (* From the premise, we know that the patient is z. *)\\n  from asm have \"Patient z\" <ATP>\\n  (* The hypothesis is related to the logical proposition B, which is derived from the explanation sentence. *)\\n  (* There is a logical relation Implies(A, B), Implies(interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients, patient has two potential treatment options) *)\\n  (* Since the patient z is related to the interchangeability of Olaparib and Rucaparib as PARP1 inhibitors, we can infer that there are two potential treatment options for this patient. *)\\n  then have \"\u2203x y. TreatmentOption x \u2227 TreatmentOption y \u2227 Patient z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients\\nB: patient has two potential treatment options\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients, patient has two potential treatment options)\\n--------\\n\\nDerived Implications:\\n'}",
            "4 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 12.505895137786865, 'proof tactics': ['Type unification failed: Clash of types \"entity\" and \"event\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  For :: event \\\\<Rightarrow> entity \\\\<Rightarrow> bool\\nOperand:   x :: entity\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_1_4\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Olaparib :: \"entity \u21d2 bool\"\\n  Rucaparib :: \"entity \u21d2 bool\"\\n  PARP1Inhibitor :: \"entity \u21d2 bool\"\\n  ProstateCancerPatient :: \"entity \u21d2 bool\"\\n  LicensedFor :: \"entity \u21d2 entity \u21d2 bool\"\\n  LeadsTo :: \"event \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  TreatmentOption :: \"event \u21d2 bool\"\\n  Potential :: \"event \u21d2 bool\"\\n  For :: \"event \u21d2 entity \u21d2 bool\"\\n  AccessTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  Implies :: \"event \u21d2 bool\"\\n  AvailableFor :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: The interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients leads to the existence of two potential treatment options for the patient *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z. Olaparib x \u2227 Rucaparib y \u2227 PARP1Inhibitor z \u2227 ProstateCancerPatient z \u2227 LicensedFor z x \u2227 LicensedFor z y \u2227 LeadsTo e1 \u2227 Patient x \u2227 TreatmentOption e1 \u2227 Potential e1 \u2227 For e1 z\"\\n\\n(* Explanation 2: The patient having access to Olaparib and Rucaparib as PARP1 inhibitors implies that there are two potential treatment options available for the patient *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z. Olaparib x \u2227 Rucaparib y \u2227 PARP1Inhibitor z \u2227 Patient x \u2227 AccessTo x y \u2227 AccessTo x z \u2227 Implies e2 \u2227 TreatmentOption e2 \u2227 Potential e2 \u2227 AvailableFor e2 x\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"ProstateCancerPatient x\"\\n  (* Hypothesis: There are two potential treatment options for this patient *)\\n shows \"\u2203x y. Patient x \u2227 TreatmentOption y \u2227 Potential y \u2227 For x y\"\\nproof -\\n  (* From the known information, we have ProstateCancerPatient x. *)\\n  from asm have \"ProstateCancerPatient x\" <ATP>\\n  (* The hypothesis involves the existence of two potential treatment options for the patient. *)\\n  (* There is a logical relation Implies(A, B), Implies(interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients, existence of two potential treatment options for the patient) *)\\n  (* Both A and B are from explanatory sentence 1. *)\\n  (* We can infer the existence of two potential treatment options for the patient. *)\\n  then have \"\u2203x y. Patient x \u2227 TreatmentOption y \u2227 Potential y \u2227 For x y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients\\nB: existence of two potential treatment options for the patient\\nC: patient having access to Olaparib and Rucaparib as PARP1 inhibitors\\nD: two potential treatment options available for the patient\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients, existence of two potential treatment options for the patient)\\n--------\\nEquivalent(C, D)\\nEquivalent(patient having access to Olaparib and Rucaparib as PARP1 inhibitors, two potential treatment options available for the patient)\\n--------\\n\\nDerived Implications:\\nImplies(D, C)\\nImplies(two potential treatment options available for the patient, patient having access to Olaparib and Rucaparib as PARP1 inhibitors)\\n--------\\nImplies(C, D)\\nImplies(patient having access to Olaparib and Rucaparib as PARP1 inhibitors, two potential treatment options available for the patient)\\n--------\\nImplies(Not(D), Not(C))\\nImplies(Not(two potential treatment options available for the patient), Not(patient having access to Olaparib and Rucaparib as PARP1 inhibitors))\\n--------\\nImplies(Not(C), Not(D))\\nImplies(Not(patient having access to Olaparib and Rucaparib as PARP1 inhibitors), Not(two potential treatment options available for the patient))\\n--------\\n'}",
            "5 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_1_5\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Olaparib :: \"entity \u21d2 bool\"\\n  Rucaparib :: \"entity \u21d2 bool\"\\n  PARP1Inhibitor :: \"entity \u21d2 bool\"\\n  ProstateCancerPatient :: \"entity \u21d2 bool\"\\n  LeadsTo :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  TreatmentOption :: \"entity \u21d2 bool\"\\n  PatientHavingAccess :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: The interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients leads to the existence of two potential treatment options for the patient *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z. Olaparib x \u2227 Rucaparib y \u2227 PARP1Inhibitor z \u2227 ProstateCancerPatient z \u2227 LeadsTo e \u2227 Patient e z \u2227 TreatmentOption x \u2227 TreatmentOption y\"\\n\\n(* Explanation 2: The patient having access to Olaparib and Rucaparib as PARP1 inhibitors implies that there are two potential treatment options available for the patient *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z. Olaparib x \u2227 Rucaparib y \u2227 PARP1Inhibitor z \u2227 PatientHavingAccess e \u2227 Patient e z \u2227 TreatmentOption x \u2227 TreatmentOption y\"\\n\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient x x\"\\n  (* Hypothesis: There are two potential treatment options for this patient *)\\n  shows \"\u2203x y. Patient x x \u2227 TreatmentOption y\"\\nproof -\\n  (* From the premise, we know that the patient is related to the patient event x. *)\\n  from asm have \"Patient x x\" <ATP>\\n  (* There are two relevant explanatory sentences that connect the patient to the treatment options. *)\\n  (* We have the logical relation Implies(A, B), Implies(interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients, existence of two potential treatment options for the patient) *)\\n  (* We also have the logical relation Equivalent(C, D), Equivalent(patient having access to Olaparib and Rucaparib as PARP1 inhibitors, two potential treatment options available for the patient) *)\\n  (* From the Equivalent relation, we can infer the existence of two potential treatment options for the patient. *)\\n  then have \"\u2203x y. Patient x x \u2227 TreatmentOption y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients\\nB: existence of two potential treatment options for the patient\\nC: patient having access to Olaparib and Rucaparib as PARP1 inhibitors\\nD: two potential treatment options available for the patient\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients, existence of two potential treatment options for the patient)\\n--------\\nEquivalent(C, D)\\nEquivalent(patient having access to Olaparib and Rucaparib as PARP1 inhibitors, two potential treatment options available for the patient)\\n--------\\n\\nDerived Implications:\\nImplies(D, C)\\nImplies(two potential treatment options available for the patient, patient having access to Olaparib and Rucaparib as PARP1 inhibitors)\\n--------\\nImplies(C, D)\\nImplies(patient having access to Olaparib and Rucaparib as PARP1 inhibitors, two potential treatment options available for the patient)\\n--------\\nImplies(Not(D), Not(C))\\nImplies(Not(two potential treatment options available for the patient), Not(patient having access to Olaparib and Rucaparib as PARP1 inhibitors))\\n--------\\nImplies(Not(C), Not(D))\\nImplies(Not(patient having access to Olaparib and Rucaparib as PARP1 inhibitors), Not(two potential treatment options available for the patient))\\n--------\\n'}",
            "6 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_1_6\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Olaparib :: \"entity \u21d2 bool\"\\n  Rucaparib :: \"entity \u21d2 bool\"\\n  PARP1Inhibitor :: \"entity \u21d2 bool\"\\n  ProstateCancerPatient :: \"entity \u21d2 bool\"\\n  LicensedFor :: \"entity \u21d2 entity \u21d2 bool\"\\n  LeadsTo :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  TreatmentOption :: \"event \u21d2 entity \u21d2 bool\"\\n  Potential :: \"entity \u21d2 bool\"\\n  AccessTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  Implies :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: The interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients leads to the existence of two potential treatment options for the patient *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z. Olaparib x \u2227 Rucaparib y \u2227 PARP1Inhibitor z \u2227 ProstateCancerPatient z \u2227 LicensedFor z x \u2227 LicensedFor z y \u2227 LeadsTo e \u2227 Patient e z \u2227 TreatmentOption e x \u2227 TreatmentOption e y \u2227 Potential x \u2227 Potential y\"\\n\\n(* Explanation 2: The patient having access to Olaparib and Rucaparib as PARP1 inhibitors implies that there are two potential treatment options available for the patient *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z. Patient x \u2227 Olaparib y \u2227 Rucaparib z \u2227 PARP1Inhibitor y \u2227 PARP1Inhibitor z \u2227 AccessTo x y \u2227 AccessTo x z \u2227 Implies e \u2227 TreatmentOption e y \u2227 TreatmentOption e z \u2227 Potential y \u2227 Potential z\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x\"\\n  (* Hypothesis: There are two potential treatment options for this patient *)\\n shows \"\u2203x y. Patient x \u2227 TreatmentOption y \u2227 Potential y \u2227 AccessTo x y\"\\nproof -\\n  (* From the premise, we know that the patient is x. *)\\n  from asm have \"Patient x\" <ATP>\\n  (* There is a logical relation Implies(A, B), Implies(interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients, existence of two potential treatment options for the patient) *)\\n  (* We can infer the existence of two potential treatment options for the patient. *)\\n  then have \"\u2203x y. Patient x \u2227 TreatmentOption y \u2227 Potential y \u2227 AccessTo x y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients\\nB: existence of two potential treatment options for the patient\\nC: patient having access to Olaparib and Rucaparib as PARP1 inhibitors\\nD: two potential treatment options available for the patient\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients, existence of two potential treatment options for the patient)\\n--------\\nEquivalent(C, D)\\nEquivalent(patient having access to Olaparib and Rucaparib as PARP1 inhibitors, two potential treatment options available for the patient)\\n--------\\n\\nDerived Implications:\\nImplies(D, C)\\nImplies(two potential treatment options available for the patient, patient having access to Olaparib and Rucaparib as PARP1 inhibitors)\\n--------\\nImplies(C, D)\\nImplies(patient having access to Olaparib and Rucaparib as PARP1 inhibitors, two potential treatment options available for the patient)\\n--------\\nImplies(Not(D), Not(C))\\nImplies(Not(two potential treatment options available for the patient), Not(patient having access to Olaparib and Rucaparib as PARP1 inhibitors))\\n--------\\nImplies(Not(C), Not(D))\\nImplies(Not(patient having access to Olaparib and Rucaparib as PARP1 inhibitors), Not(two potential treatment options available for the patient))\\n--------\\n'}",
            "7 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_1_7\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Olaparib :: \"entity \u21d2 bool\"\\n  Rucaparib :: \"entity \u21d2 bool\"\\n  PARP1Inhibitor :: \"entity \u21d2 bool\"\\n  ProstateCancerPatient :: \"entity \u21d2 bool\"\\n  LeadsTo :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  TreatmentOption :: \"entity \u21d2 bool\"\\n  Implies :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: The interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients leads to the existence of two potential treatment options for the patient *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z. Olaparib x \u2227 Rucaparib y \u2227 PARP1Inhibitor z \u2227 ProstateCancerPatient z \u2227 LeadsTo e \u2227 Agent e z \u2227 Patient e z \u2227 TreatmentOption x \u2227 TreatmentOption y\"\\n\\n(* Explanation 2: The patient having access to Olaparib and Rucaparib as PARP1 inhibitors implies that there are two potential treatment options available for the patient *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z. Olaparib x \u2227 Rucaparib y \u2227 PARP1Inhibitor z \u2227 Patient z \u2227 Implies e \u2227 Agent e z \u2227 TreatmentOption x \u2227 TreatmentOption y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient x\"\\n  (* Hypothesis: There are two potential treatment options for this patient *)\\n  shows \"\u2203x y. Patient x \u2227 TreatmentOption y\"\\nproof -\\n  (* From the premise, we know that the patient has access to Olaparib and Rucaparib as PARP1 inhibitors. *)\\n  from asm have \"Patient x\" <ATP>\\n  (* There is a logical relation Implies(C, D), Implies(patient having access to Olaparib and Rucaparib as PARP1 inhibitors, two potential treatment options available for the patient) *)\\n  (* Both C and D are from explanatory sentence 2, we can infer the existence of two potential treatment options. *)\\n  then have \"\u2203x y. Patient x \u2227 TreatmentOption y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients\\nB: existence of two potential treatment options for the patient\\nC: patient having access to Olaparib and Rucaparib as PARP1 inhibitors\\nD: two potential treatment options available for the patient\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients, existence of two potential treatment options for the patient)\\n--------\\nEquivalent(C, D)\\nEquivalent(patient having access to Olaparib and Rucaparib as PARP1 inhibitors, two potential treatment options available for the patient)\\n--------\\n\\nDerived Implications:\\nImplies(D, C)\\nImplies(two potential treatment options available for the patient, patient having access to Olaparib and Rucaparib as PARP1 inhibitors)\\n--------\\nImplies(C, D)\\nImplies(patient having access to Olaparib and Rucaparib as PARP1 inhibitors, two potential treatment options available for the patient)\\n--------\\nImplies(Not(D), Not(C))\\nImplies(Not(two potential treatment options available for the patient), Not(patient having access to Olaparib and Rucaparib as PARP1 inhibitors))\\n--------\\nImplies(Not(C), Not(D))\\nImplies(Not(patient having access to Olaparib and Rucaparib as PARP1 inhibitors), Not(two potential treatment options available for the patient))\\n--------\\n'}",
            "8 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_1_8\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Olaparib :: \"entity \u21d2 bool\"\\n  Rucaparib :: \"entity \u21d2 bool\"\\n  PARP1Inhibitor :: \"entity \u21d2 bool\"\\n  ProstateCancerPatient :: \"entity \u21d2 bool\"\\n  LeadsTo :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  TreatmentOption :: \"entity \u21d2 bool\"\\n  PatientHavingAccess :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: The interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients leads to the existence of two potential treatment options for the patient *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z. Olaparib x \u2227 Rucaparib y \u2227 PARP1Inhibitor z \u2227 ProstateCancerPatient z \u2227 LeadsTo e \u2227 Patient e z \u2227 TreatmentOption x \u2227 TreatmentOption y\"\\n\\n(* Explanation 2: The patient having access to Olaparib and Rucaparib as PARP1 inhibitors implies that there are two potential treatment options available for the patient *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z. Olaparib x \u2227 Rucaparib y \u2227 PARP1Inhibitor z \u2227 PatientHavingAccess e \u2227 Patient e z \u2227 TreatmentOption x \u2227 TreatmentOption y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient x\"\\n  (* Hypothesis: There are two potential treatment options for this patient *)\\n  shows \"\u2203x y. Patient x \u2227 TreatmentOption y\"\\nproof -\\n  (* From the premise, we know that the patient exists. *)\\n  from asm have \"Patient x\" <ATP>\\n  (* There are two relevant explanation sentences: Explanation 1 and Explanation 2. *)\\n  (* Explanation 1 states that the interchangeability of Olaparib and Rucaparib as PARP1 inhibitors leads to two potential treatment options. *)\\n  (* Explanation 2 states that the patient having access to Olaparib and Rucaparib as PARP1 inhibitors implies two potential treatment options. *)\\n  (* There is a logical relation Implies(A, B), Implies(interchangeability of Olaparib and Rucaparib as PARP1 inhibitors, existence of two potential treatment options for the patient) *)\\n  (* There is a logical relation Equivalent(C, D), Equivalent(patient having access to Olaparib and Rucaparib as PARP1 inhibitors, two potential treatment options available for the patient) *)\\n  (* We can use these relations to infer the existence of two potential treatment options for the patient. *)\\n  then have \"\u2203x y. Patient x \u2227 TreatmentOption y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients\\nB: existence of two potential treatment options for the patient\\nC: patient having access to Olaparib and Rucaparib as PARP1 inhibitors\\nD: two potential treatment options available for the patient\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients, existence of two potential treatment options for the patient)\\n--------\\nEquivalent(C, D)\\nEquivalent(patient having access to Olaparib and Rucaparib as PARP1 inhibitors, two potential treatment options available for the patient)\\n--------\\n\\nDerived Implications:\\nImplies(D, C)\\nImplies(two potential treatment options available for the patient, patient having access to Olaparib and Rucaparib as PARP1 inhibitors)\\n--------\\nImplies(C, D)\\nImplies(patient having access to Olaparib and Rucaparib as PARP1 inhibitors, two potential treatment options available for the patient)\\n--------\\nImplies(Not(D), Not(C))\\nImplies(Not(two potential treatment options available for the patient), Not(patient having access to Olaparib and Rucaparib as PARP1 inhibitors))\\n--------\\nImplies(Not(C), Not(D))\\nImplies(Not(patient having access to Olaparib and Rucaparib as PARP1 inhibitors), Not(two potential treatment options available for the patient))\\n--------\\n'}",
            "9 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_1_9\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Olaparib :: \"entity \u21d2 bool\"\\n  Rucaparib :: \"entity \u21d2 bool\"\\n  PARP1Inhibitor :: \"entity \u21d2 bool\"\\n  ProstateCancerPatient :: \"entity \u21d2 bool\"\\n  LicensedFor :: \"entity \u21d2 entity \u21d2 bool\"\\n  LeadsTo :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  TreatmentOption :: \"event \u21d2 entity \u21d2 bool\"\\n  Potential :: \"entity \u21d2 bool\"\\n  AccessTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  Implies :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: The interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients leads to the existence of two potential treatment options for the patient *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z. Olaparib x \u2227 Rucaparib y \u2227 PARP1Inhibitor z \u2227 ProstateCancerPatient z \u2227 LicensedFor z x \u2227 LicensedFor z y \u2227 LeadsTo e \u2227 Patient e z \u2227 TreatmentOption e x \u2227 TreatmentOption e y \u2227 Potential x \u2227 Potential y\"\\n\\n(* Explanation 2: The patient having access to Olaparib and Rucaparib as PARP1 inhibitors implies that there are two potential treatment options available for the patient *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z. Patient x \u2227 Olaparib y \u2227 Rucaparib z \u2227 PARP1Inhibitor y \u2227 PARP1Inhibitor z \u2227 AccessTo x y \u2227 AccessTo x z \u2227 Implies e \u2227 TreatmentOption e y \u2227 TreatmentOption e z \u2227 Potential y \u2227 Potential z\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x\"\\n  (* Hypothesis: There are two potential treatment options for this patient *)\\n shows \"\u2203x y. Patient x \u2227 TreatmentOption y \u2227 Potential y \u2227 LeadsTo x y\"\\nproof -\\n  (* From the premise, we know that the patient is x. *)\\n  from asm have \"Patient x\" <ATP>\\n  (* There is a logical relation Implies(A, B), Implies(interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients, existence of two potential treatment options for the patient) *)\\n  (* We can infer the existence of two potential treatment options for the patient from the interchangeability of Olaparib and Rucaparib as PARP1 inhibitors. *)\\n  then have \"\u2203x y. Patient x \u2227 TreatmentOption y \u2227 Potential y \u2227 LeadsTo x y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients\\nB: existence of two potential treatment options for the patient\\nC: patient having access to Olaparib and Rucaparib as PARP1 inhibitors\\nD: two potential treatment options available for the patient\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients, existence of two potential treatment options for the patient)\\n--------\\nEquivalent(C, D)\\nEquivalent(patient having access to Olaparib and Rucaparib as PARP1 inhibitors, two potential treatment options available for the patient)\\n--------\\n\\nDerived Implications:\\nImplies(D, C)\\nImplies(two potential treatment options available for the patient, patient having access to Olaparib and Rucaparib as PARP1 inhibitors)\\n--------\\nImplies(C, D)\\nImplies(patient having access to Olaparib and Rucaparib as PARP1 inhibitors, two potential treatment options available for the patient)\\n--------\\nImplies(Not(D), Not(C))\\nImplies(Not(two potential treatment options available for the patient), Not(patient having access to Olaparib and Rucaparib as PARP1 inhibitors))\\n--------\\nImplies(Not(C), Not(D))\\nImplies(Not(patient having access to Olaparib and Rucaparib as PARP1 inhibitors), Not(two potential treatment options available for the patient))\\n--------\\n'}",
            "10 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_1_10\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Olaparib :: \"entity \u21d2 bool\"\\n  Rucaparib :: \"entity \u21d2 bool\"\\n  PARP1Inhibitor :: \"entity \u21d2 bool\"\\n  ProstateCancerPatient :: \"entity \u21d2 bool\"\\n  LeadsTo :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  TreatmentOption :: \"entity \u21d2 bool\"\\n  PatientHavingAccess :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: The interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients leads to the existence of two potential treatment options for the patient *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z. Olaparib x \u2227 Rucaparib y \u2227 PARP1Inhibitor z \u2227 ProstateCancerPatient z \u2227 LeadsTo e \u2227 Patient e z \u2227 TreatmentOption x \u2227 TreatmentOption y\"\\n\\n(* Explanation 2: The patient having access to Olaparib and Rucaparib as PARP1 inhibitors implies that there are two potential treatment options available for the patient *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z. Olaparib x \u2227 Rucaparib y \u2227 PARP1Inhibitor z \u2227 PatientHavingAccess e \u2227 Patient e z \u2227 TreatmentOption x \u2227 TreatmentOption y\"\\n\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient x\"\\n  (* Hypothesis: There are two potential treatment options for this patient *)\\n  shows \"\u2203x y. Patient x \u2227 TreatmentOption y\"\\nproof -\\n  (* From the premise, we know that the patient exists. *)\\n  from asm have \"Patient x\" <ATP>\\n  (* There is a logical relation Implies(C, D), Implies(patient having access to Olaparib and Rucaparib as PARP1 inhibitors, two potential treatment options available for the patient) *)\\n  (* Both C and D are from explanatory sentence 2, we can infer the existence of two potential treatment options. *)\\n  then obtain a b where \"Patient x \u2227 TreatmentOption a \u2227 TreatmentOption b\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients\\nB: existence of two potential treatment options for the patient\\nC: patient having access to Olaparib and Rucaparib as PARP1 inhibitors\\nD: two potential treatment options available for the patient\\n\\nLogical Relations:\\nEquivalent(A, B)\\nEquivalent(interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients, existence of two potential treatment options for the patient)\\n--------\\nImplies(C, D)\\nImplies(patient having access to Olaparib and Rucaparib as PARP1 inhibitors, two potential treatment options available for the patient)\\n--------\\n\\nDerived Implications:\\nImplies(Not(B), Not(A))\\nImplies(Not(existence of two potential treatment options for the patient), Not(interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients))\\n--------\\nImplies(Not(A), Not(B))\\nImplies(Not(interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients), Not(existence of two potential treatment options for the patient))\\n--------\\nImplies(B, A)\\nImplies(existence of two potential treatment options for the patient, interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients)\\n--------\\nImplies(A, B)\\nImplies(interchangeability of Olaparib and Rucaparib as PARP1 inhibitors licensed for use in prostate cancer patients, existence of two potential treatment options for the patient)\\n--------\\n'}"
        ]
    }
}